University of California San Francisco
Give to UCSF
Three injectable medications, Wegovy, Ozempic and Mounjaro, are often taken as weight management drugs. UCSF health experts weigh in on the benefits and risks of taking the medications for obesity.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
An Oregon prison is testing a Norwegian-inspired approach to prison reform that’s designed to bring greater humanity to corrections and improve conditions for staff and prison residents. This includes reducing the use of solitary confinement.
Could the microbes in our guts be a treatment for asthma? UCSF scientists are working to find out.
Scientist proved for the first time that kidney cells, housed in an implantable device functioning as an artificial kidney, can survive inside the body of an animal.
A brain implant and digital avatar allow a paralyzed stroke survivor to speak with for first time in 18 years with the help of artificial intelligence.
Gal-3C, a galectin-3 inhibitor, shows promise in limiting post-MI scarring, improving cardiac function, and outperforming current therapies.
The United States health system is poorly equipped to serve patients living alone who are also experiencing cognitive decline.
Study finds DOACs may lower recurrent VTE risk over warfarin in extended treatment. Observational evidence supports DOAC use.
A newly identified platelet factor 4 (PF4) was found to help rejuvenate the old brain and boost the young brain, potentially opening the door to new therapies that aim to restore brain function
